| Compound | Prostamax |
|---|---|
| Category | Khavinson prostate bioregulator |
| Class | Other Injectables |
| Evidence tier | Minimal evidence |
| WADA status | Not individually listed; verify current status if subject to testing |
| Sold on this site | No — this is a reference database |
Overview
Prostamax — a khavinson prostate bioregulator — sits in the "Minimal evidence" tier of this catalog. There is little or no formal study of this compound. Claims rest on anecdote, theory, or very early-stage work; risk data are absent by definition.
A short peptide from the bioregulation program claimed to target prostate tissue.
Mechanism of Action
Proposed prostate-epithelium regulation within the bioregulation theory.
Research and Evidence
Regional literature only.
Safety and Side Effects
Sparse data.
Frequently Asked Questions
What is the evidence tier of Prostamax?
Prostamax is graded "Minimal evidence" on this site. There is little or no formal study of this compound. Claims rest on anecdote, theory, or very early-stage work; risk data are absent by definition.
Is Prostamax an approved medicine?
No. Minimal evidence means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.
Where can I read the primary studies for Prostamax?
The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.
References
- ClinicalTrials.gov — search for Prostamax studies. [source]
Evidence tier: Minimal evidence · Last reviewed: 2026-09-05 · Sources cited below.